BURLINGTON, Mass., Oct. 14, 2014 /PRNewswire/ — Decision Resources Group finds that the Parkinson’s disease (PD) pharmacotherapy market will grow 5 percent annually from $2.3 billion in 2013 to $3.8 billion in 2023. This growth will be fueled by the launch of several emerging therapies—including new molecular entities in established drug classes, reformulations of time-tested products, and novel first-in-class entrants that target a range of clinically-important subpopulations facing diverse unmet needs.
Other key findings from the Pharmacor report entitled Parkinson’s Disease:
- Improved rescue therapies: Interviewed experts show enthusiasm for Civitas’ CVT-301 as an effective, patient-friendly alternative to injectable formulations of apomorphine for PD patients experiencing “off” episodes. Decision Resources Group forecasts CVT-301 will earn approximately $700 million in the U.S. market in 2023 with the potential for additional revenues through a global launch, prospects which appear stronger following Acorda Therapeutics’ September 2014 announcement to acquire Civitas.
- First approval for PD-associated psychosis: Acadia’s Nuplazid is poised to become the first therapy approved specifically to treat PD-associated psychosis, a key comorbidity that is undertreated and underserved by current off-label options, which can exacerbate motor symptoms. Following a projected U.S. and European launch beginning in 2016, we forecast Nuplazid will increase the number of patients receiving an antipsychotic for PD-associated psychosis and garner PD sales of approximately $400 million in 2023.
- Reformulations of levodopa: Although levodopa remains the patient share leader in PD, the pharmacokinetic shortcomings of marketed levodopa products leave interviewed experts open to additional reformulations. However, based on available data, it remains unclear whether emerging brands such as Impax’s Rytary will deliver a clinically-meaningful advance for patients needing levodopa, which has been generically available for many years.
Comments from Decision Resources Group Analyst Tamara Blutstein, Ph.D.:
- “Opportunity still remains for adjunctive therapies to address the motor response complications associated with chronic levodopa treatment. Nevertheless, competition from clinical mainstays will make it difficult for late entrants like Newron/Zambon/Meiji Seika Pharma’s monoamine oxidase B inhibitor safinamide, Bial/Ono’s catechol-O-methyltransferase inhibitor opicapone, and Adamas’ extended-release amantadine formulation Nurelin to garner a substantial share of the market unless significant clinical differentiation can be shown.”
- “Near-term opportunity also exists for therapies that target other motor symptoms that are not adequately controlled with current treatments, including gait dysfunction, freezing, and postural imbalance—but the real future of PD treatment lies in disease-modifying therapies, a number of which are currently in early-stage development. Evolving insights into the etiology and pathology of PD will help identify additional targets for disease-modifying therapies, which will remain an important focus of therapeutic development in PD over the long term.”
About Decision Resources Group
Decision Resources Group offers best-in-class, high-value information and insights on critical issues within the healthcare industry. Clients rely on this analysis and data to make informed decisions. Find out more at www.DecisionResourcesGroup.com.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact:
Decision Resources Group